Free Ambulance Service Saves Lives in Yobe State
Yobe State's free ambulance service is saving lives by providing critical access to emergency medical care.
Featured Stories
All Stories →
Kano’s Ghari Community Trained to Recognize Prolonged Labor
Kano's Ghari community is trained to recognize prolonged labor warning signs and seek timely medical care through art-based initiatives.
Nigeria launches global partnership to tackle sickle cell disease
Nigeria launches a global partnership to tackle sickle cell disease, affecting 150,000 babies annually, with WHO and UNICEF involvement.
Nigeria Struggles to Fund Maternal Health Services
Nigeria's maternal health services face a funding crisis, impacting women's access to essential care and increasing preventable deaths.
Diet Links
More →
Monitor Picks
More →
Free Ambulance Service Saves Lives in Yobe State
Nigeria Struggles to Fund Maternal Health Services
West Africa seeks Lassa fever vaccine funding
BP Trends
More →
Drug Doses
More →
Stress Checks
More →
WHO Aims to Detect Outbreaks Within 24 Hours by 2030
Popular Posts
Refresh ↺MENA Health Strategy Needed Amid Diverse Challenges
A MENA health strategy is needed to address the region's distinct challenges, including war, instability, and economic crises.
Mileage Mistakes Runners Make Before a Race
Common running mistakes include incorrect mileage before a race, affecting performance and injury rate, with running mileage.
50-Year-Old Trail Runner Surprises With Fastest Hardrock Time
A 50-year-old trail runner sets the fastest Hardrock 100 record, showing age isn't a barrier to ultramarathon success.
Top treadmills to watch in 2026
Discover the top treadmills of 2026 with advanced features, energy efficiency, and interactive training for all fitness levels.
Abu Dhabi Designates Three Breast Cancer Centers of Excellence
Abu Dhabi designates three breast cancer centers of excellence to strengthen specialized care across the emirate. Burjeel Cancer Institute, Cleveland…
Breakthrough pancreatic cancer drug doubles survival in late-stage patients
FDA-approved daraxonrasib may double survival for late-stage pancreatic cancer patients after chemotherapy failure, per University of Chicago trial data.